Elevated brain monoamine oxidase activity in SIV-and HIV-associated neurological disease

Journal of Infectious Diseases

Volumn 210, Issue 6, 2014, Pages 904-912

  Meulendyke, Kelly A ^a   Ubaida Mohien, Ceereena ^a   Drewes, Julia L ^a   Liao, Zhaohao ^a   Gama, Lucio ^a   Witwer, Kenneth W ^a   Graham, David R ^a   Zink, M Christine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Monoamine oxidase; Neuroinflammation; Oxidative stress; Reactive oxygen species; SIV

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CD68 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM INFECTION; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; ENCEPHALITIS; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA NEMESTRINA; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS LOAD;

HIV; MONOAMINE OXIDASE; NEUROINFLAMMATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIV;

ADULT; AIDS DEMENTIA COMPLEX; ANIMALS; BRAIN; BRAIN CHEMISTRY; CORPUS STRIATUM; FEMALE; GENE EXPRESSION PROFILING; GLUTATHIONE; HUMANS; MACACA NEMESTRINA; MALE; MIDDLE AGED; MONOAMINE OXIDASE; OXIDATIVE STRESS; REAL-TIME POLYMERASE CHAIN REACTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRAL LOAD;

EID: 84907364728     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu194     Document Type: Conference Paper

References (49)

1. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5:69-81.
2. Kaul M, Lipton SA. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 2006; 4:307-18.
3. Rumbaugh JA, Nath A. Developments in HIV neuropathogenesis. Curr Pharm Des 2006; 12:1023-44.
4. Steiner J, Haughey N, Li W, et al. Oxidative stress and therapeutic approaches in HIV dementia. Antioxid Redox Signal 2006; 8:2089-100.
5. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59:1609-23.
6. Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002; 25:537-62.
7. Israel N, Gougerot-Pocidalo MA, Aillet F, Virelizier JL. Redox status of cells influences constitutive or induced NF-kappa B translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J Immunol 1992; 149:3386-93.
8. Piette J, Legrand-Poels S. HIV-1 reactivation after an oxidative stress mediated by different reactive oxygen species. Chem Biol Interact 1994; 91:79-89.
9. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10:2247-58.
10. Pocernich CB, Sultana R, Mohmmad-Abdul H, Nath A, Butterfield DA. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res Brain Res Rev 2005; 50:14-26.
11. Becker JT, Sanders J, Madsen SK, et al. Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging Behav 2011; 5:77-85.
12. Kumar AM, Borodowsky I, Fernandez B, Gonzalez L, Kumar M. Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptasepolymerase chain reaction. J Neurovirol 2007; 13:210-24.
13. Wiley CA, Soontornniyomkij V, Radhakrishnan L, et al. Distribution of brain HIV load in AIDS. Brain Pathol 1998; 8:277-84.
14. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986; 19:525-35.
15. Agrawal L, Louboutin JP, Marusich E, Reyes BA, Van Bockstaele EJ, Strayer DS. Dopaminergic neurotoxicity of HIV-1 gp120: reactive oxygen species as signaling intermediates. Brain Res 2010; 1306:116-30.
16. Czub S, Koutsilieri E, Sopper S, et al. Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol 2001; 101:85-91.
17. Meulendyke KA, Pletnikov MV, Engle EL, Tarwater PM, Graham DR, Zink MC. Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease. J Neuroimmune Pharmacol 2012; 7:454-64.
18. Sardar AM, Czudek C, Reynolds GP. Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 1996; 7:910-2.
19. Scheller C, Sopper S, Jenuwein M, et al. Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem 2005; 95:377-87.
20. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J Neurovirol 2011; 17:26-40.
21. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science 1985; 230:181-3.
22. Youdim MB, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect 1993; 91:181-95.
23. Mallajosyula JK, Kaur D, Chinta SJ, et al. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One 2008; 3: e1616.
24. Siddiqui A, Mallajosyula JK, Rane A, Andersen JK. Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression. Neurobiol Dis 2010; 40:444-8.
25. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci U S A 1989; 86:1398-400.
26. Wong WK, Ou XM, Chen K, Shih JC. Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1. J Biol Chem 2002; 277:22222-30.
27. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2:717-26.
28. Medders KE, Kaul M. Mitogen-activated protein kinase p38 in HIV infection and associated brain injury. J Neuroimmune Pharmacol 2011; 6:202-15.
29. Shiizaki S, Naguro I, Ichijo H. Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling. Adv Biol Regul 2013; 53:135-44.
30. Barber SA, Uhrlaub JL, DeWitt JB, Tarwater PM, Zink MC. Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis. Am J Pathol 2004; 164: 355-62.
31. Zink MC, Suryanarayana K, Mankowski JL, et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 1999; 73:10480-8.
32. Clements JE, Mankowski JL, Gama L, Zink MC. The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. J Neurovirol 2008; 14:309-17.
33. Weed MR, Hienz RD, Brady JV, et al. Central nervous system correlates of behavioral deficits following simian immunodeficiency virus infection. J Neurovirol 2003; 9:452-64.
34. Witwer KW, Gama L, Li M, et al. Coordinated regulation of SIV replication and immune responses in the CNS. PLoS One 2009; 4:e8129.
35. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000; 62:649-71.
36. Follstaedt SC, Barber SA, Zink MC. Mechanisms of minocyclineinduced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1. J Neurovirol 2008; 14:376-88.
37. Fowler CJ,Wiberg A, Oreland L, Marcusson J,Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 1980; 49:1-20.
38. Cao X, Rui L, Pennington PR, et al. Serine 209 resides within a putative p38(MAPK) consensus motif and regulates monoamine oxidase-A activity. J Neurochem 2009; 111:101-10.
39. Chaudhuri AD, Yelamanchili SV, Fox HS. MicroRNA-142 reduces monoamine oxidase A expression and activity in neuronal cells by downregulating SIRT1. PLoS One 2013; 8:e79579.
40. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005; 64:529-36.
41. Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010; 7:15.
42. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology 1997; 49:142-6.
43. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology 1998; 50:645-51.
44. Nakasujja N, Miyahara S, Evans S, et al. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology 2013; 80:196-202.
45. Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIVassociated cognitive impairment: results from a randomized trial. Neurology 2011; 77:1135-42.
46. Evans SR, Yeh TM, Sacktor N, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 2007; 8:437-46.
47. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000; 54: 233-5.
48. Schifitto G, Yiannoutsos CT, Ernst T, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology 2009; 73:1975-81.
49. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007; 69:1314-21.